November 13, 2014

 Janssen Pharmaceuticals announced that the Food and Drug Administration approved the company's supplemental new drug application for the once-monthly Invega Sustenna (paliperidone palmitate), an antipsychotic used to treat schizoaffective disorder as either monotherapy or adjunctive therapy. 

November 11, 2014

Teva Pharmaceuticals announced the introduction of dexmethylphenidate hydrochloride extended-release capsules, CII, in a 5-mg strength.

November 4, 2014

Rogaine brand on Tuesday announced the launch of Women's Rogaine 5% Minoxidil topical aerosol, the first and only once-daily treatment approved by the Food and Drug Administration for the treatment of female pattern hair loss, according to the brand. 

September 26, 2014

Camber Pharmaceuticals announced the launch of raloxifene hydrochloride, USP tablets in 60-mg dosage strengths.

July 23, 2014

Mylan on Wednesday announced that U.S. District Court for the district of New Jersey granted a temporary restraining order against Apotex Inc. and Apotex Corp. relating to Paroxetine CR.

July 17, 2014

Mylan on Thursday announced that the U.S. District Court for the district of New Jersey granted its motion for a permanent injunction against GlaxoSmithKline in relation to paroxetine CR, the generic version of GSK's Paxil CR.

May 29, 2014

Teva Pharmaceuticals announced the introduction and availability of dexmethylphenidate hydrochloride extended-release capsules, CII, in 15 mg and 30 mg strengths.

May 27, 2014

The May/June 2014 Skin & Itch Relief Ingredient Guide breaks down the indication, ingredients, purpose and dosage of AmLactin Cerapeutic Restoring, Cetaphil RestoraDerm Skin Restoring, Olay Advanced Healing Intensive, Curél Intesive Healing, Nivea Extended Moisture, Aveeno 1% Hydrocortisone Anti-itch, Extra Strength Benadryl Itch Stopping and Corizone 10 Anti-itch Ultra Moisturing Creme Plus.

May 15, 2014

Actavis has reached an agreement with Janssen Pharmaceuticals to continue supplying the authorized generic version of Janssen's Concerta (methylphenidate hydrochloride extended-release tablets), the company announced.

May 9, 2014

Ajanta Pharma USA on Friday announced the launch of risperidone tablets (0.25-mg, 0.5-mg, 1-mg, 2-mg, 3-mg and 4-mg), the generic version of Risperdal.

May 9, 2014

CorePharma on Thursday announced the launch of methylphenidate hydrochloride tablets USP, the generic version of Ritalin from Novartis.

April 30, 2014

The Food and Drug Administration on Tuesday granted approval to Zykadia (ceritinib) for patients with a specific type of late-stage (metastatic) non-small cell lung cancer (NSCLC).

April 1, 2014

Prasco Labs on Tuesday announced that it has signed a marketing and distribution agreement with Eli Lilly and Co. to market the authorized generic version of Evista (raloxifene hydrochloride tablets), 60 mg strength, in the United States.

April 1, 2014

Teva Pharmaceuticals on Tuesday announced the introduction and availability of Raloxifene hydrochloride tablets, USP.

March 26, 2014

The March/April 2014 Allergy Relief Ingredient Guide breaks down the indication, ingredients, purpose and dosage of Children's Claritin Chewable, Children's Allegra Allergy meltable tablets, Children's Benadryl Allergy Liquid, Nasacort Allergy 24HR, Mucinex Allergy, Hyland's 4 Kids Complete Allergy and Similasan Kids Allergy Eye Relief.

March 21, 2014

Actavis earlier this week announced that it has entered into an agreement with Noven Pharmaceuticals to settle all outstanding patent litigation related to Actavis' generic version of Daytrana (methylphenidate transdermal system).

March 17, 2014

Bristol-Myers Squibb Co. and Pfizer announced that the Food and Drug Administration approved a supplemental new drug application for Eliquis (apixaban). The drug is a preventive treatment for deep vein thrombosis, which can lead to pulmonary embolism for patients who have had hip or knee replacement surgery.

March 4, 2014

Teva Pharmaceutical Industries announced that it received approval for generic Evista (raloxifene) tablets, 60-mg, in the United States.

February 7, 2014

The January/February 2014 Vitamins and Supplements Ingredient Guide breaks down the indication, ingredients, purpose and dosage of Vitamints Immune, Centrum Specialist Immune Support, Alive! Children's Multi-Vitamin Gummy, Natrol's Melatonin, VitaMelts Multi, TruBiotics, Align and Culturelle Digestive Health Capsules.

January 24, 2014

Perrigo announced that it received final approval from the Food and Drug Administration for repaglinide tablets — a generic version of Prandin tablets.

January 23, 2014

Mylan announced that its U.S.-based subsidiary has launched repaglinide tablets, a generic version of Novo Nordisk's Prandin.

November 25, 2013

The November/December 2013 Cough, Cold and Flu Ingredient Guide breaks down the indication, ingredients, purpose and dosage of Robitussin Maximum Strength, NyQuil Severe Cold & Flu, Theraflu Warming Caplets, Coricidin HBP Cold & Flu, Tylenol Cold & Flu Severe, Hyland's Defend Severe Cold & Flu, Similasan Mucus Relief and Splintek Night Guard.

November 21, 2013

Teva has introduced a generic version of a drug used to treat attention deficit hyperactivity disorder, the company said Thursday.

November 18, 2013

Generic drug maker Mylan has launched its version of a drug for treating attention deficit hyperactivity disorder, the company said Monday.